Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Suzetrigine in Total Knee Arthroplasty

NCT07864896 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.

NCT NCT07864896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07864896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial of Suzetrigine in Total Knee Arthroplasty
Lead sponsor
Hospital for Special Surgery, New York
Phase
Phase 3
Overall status
Recruiting
Start date
October 15, 2026
Completion date
January 31, 2030
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

journavx, multimodal analgesia, nav 1.8, opioid cessation, opioid consumption, postoperative, pain, pain management, randomized controlled study, randomized controlled trial, randomized controlled trials, suzetrigine, total knee arthroplasty (tka), total knee arthroplasty \(tka\), total knee replacement, total knee replacement arthroplasty, total knee replacement surgery, total knee replacements